Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 303 of 5804
-
New lotion shows promise for rare skin disorder
Disease control Recruiting nowThis is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling appr…
Phase: PHASE2, PHASE3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to tackle tough lung cancer
Disease control Recruiting nowThis study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looki…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a mitochondrial antioxidant help manage preeclampsia?
Disease control Recruiting nowPreeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, t…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for myelofibrosis patients who failed standard therapy
Disease control Recruiting nowThis trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the moderate to high risk MF trial who are refractory, relapsed, or intolerant to JAK inhibitor . Select successful trial participants and…
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough esophageal cancer: SYS6010 trial launches
Disease control Not yet recruitingThis study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for sarcoma patients: drug combo aims to shrink tumors
Disease control Recruiting nowThis phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread fr…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Mind-Controlled tech trial launches for ALS patients
Disease control Recruiting nowFunctional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)
Phase: NA • Sponsor: Synchron, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cell therapy offers hope for tough anemia cases
Disease control Not yet recruitingThis is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in patients with autoimmune hemolytic anemia who have…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy targets hard-to-treat solid tumors
Disease control Not yet recruitingThis is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a cell secretion boost vitiligo treatment? new study aims to find out.
Disease control Not yet recruitingThe goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisf…
Phase: PHASE2, PHASE3 • Sponsor: Yohanes Firmansyah, dr, MH, MM • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Scientists hunt for clues to stop wasting in cancer
Knowledge-focused Recruiting nowCancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fun…
Phase: NA • Sponsor: China Medical University, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New surgery may help rectal cancer patients avoid permanent stoma
Disease control Recruiting nowThe goal of this clinical trial is to explore the difference in 3-year stoma-free survival between the Turnbull-Cutait delayed coloanal anastomosis (TCA) surgery and the low anterior resection combined with protective stoma (LAR) surgery in patients with low rectal cancer, as wel…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lung cancer patients: YL202 takes on chemo in major trial
Disease control Recruiting nowNon-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally advanced or metastatic non-squamous NSCLC with EGFR m…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough leukemia: capivasertib combo enters human trials
Disease control Recruiting nowThis is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, de…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can adding radiation to immunotherapy and chemotherapy boost breast cancer treatment?
Disease control Recruiting nowThis is a prospective radiation dose-finding, phase 2 expansion study of the Triple Negative (TN) cohort of the multicenter randomized study P-RAD (A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Br…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug could beat virus threat in transplant patients
Disease control Recruiting nowThis randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized su…
Phase: PHASE3 • Sponsor: SymBio Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo aims to boost transplant success in tough lymphoma
Disease control Recruiting nowIn this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to an…
Phase: PHASE2 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a new pill beat the standard for gout? large trial underway
Disease control Recruiting nowThe primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \< 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, …
Phase: PHASE3 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New HIV prevention shot tested in real-world clinics
Prevention Recruiting nowThe goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and disco…
Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC